Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Joseph L, Kim"'
Autor:
Felix Scheuplein, Florian Renner, John E. Campbell, Robert Campbell, Chris De Savi, Jan Eckmann, Holger Fischer, Jie Ge, Luke Green, Peter Jakob, Joseph L. Kim, Caitlin Kinkema, Katie McGinn, Ricardo Medina, Annemarie Müller, Nisha Perez, Emanuele Perola, Yoav Timsit, Tary Traore, Ulrike Hopfer, Stefka Tyanova, Manuel Tzouros, Ruduan Wang, Richard Woessner, Marion Dorsch, James R. Bischoff
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThe serine/threonine kinase 17B (STK17B) is involved in setting the threshold for T cell activation and its absence sensitizes T cells to suboptimal stimuli. Consequently, STK17B represents an attractive potential target for cancer immuno
Externí odkaz:
https://doaj.org/article/301b248df8e548fc8ca6b2a6315e5115
Autor:
Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel
Supplementary Figure S1. Potency against FGFR family and kinome selectivity. Supplementary Figure S2. Kinases with a cysteine at the equivalent position to Cys552 in FGFR4. Supplementary Figure S3. MALDI Mass Spectrometry of FGFR4. Supplementary Figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8961190ae57361a2b45e2b8293c97f7
https://doi.org/10.1158/2159-8290.22530420
https://doi.org/10.1158/2159-8290.22530420
Autor:
Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel
Supplementary Methods and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bdbee434896ada0f2bffee6775eee2
https://doi.org/10.1158/2159-8290.22530417
https://doi.org/10.1158/2159-8290.22530417
Autor:
Teresa L. Burgess, Richard Kendall, Robert Radinsky, Brian Belmontes, Hue Kha, Manory Fernando, Martin A. Broome, Karthik Nagapudi, Adrian L. Smith, Joseph L. Kim, Steven Vonderfecht, Mark J. Rose, Quynh Le, Carol Babij, Pedro J. Beltran, Josette Carnahan
Raf inhibitors are under clinical investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf. Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0856e6a8497363b776f8b5446fd65d
https://doi.org/10.1158/1535-7163.c.6531411.v1
https://doi.org/10.1158/1535-7163.c.6531411.v1
Autor:
Teresa L. Burgess, Richard Kendall, Robert Radinsky, Brian Belmontes, Hue Kha, Manory Fernando, Martin A. Broome, Karthik Nagapudi, Adrian L. Smith, Joseph L. Kim, Steven Vonderfecht, Mark J. Rose, Quynh Le, Carol Babij, Pedro J. Beltran, Josette Carnahan
Supplementary Data from Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c9218983b878b17334b0ead6834a74
https://doi.org/10.1158/1535-7163.22484454
https://doi.org/10.1158/1535-7163.22484454
Autor:
Alexandra K. Gardino, Erica K. Evans, Joseph L. Kim, Natasja Brooijmans, Brian L. Hodous, Beni Wolf, Christoph Lengauer
Publikováno v:
Molecular & Cellular Oncology, Vol 5, Iss 3 (2018)
Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in a variety of activation mechanisms. The challenge has been to match these insights with tailored drug discovery strategies to yiel
Externí odkaz:
https://doaj.org/article/ecaaeee92c114955a1ed8fac2d8ea24c
Autor:
Joseph L. Kim, Jean D. Boyer, Susan Duff, Michael J. Dallas, Kim Kraynyak, Prakash K. Bhuyan, Timothy A. Herring, Matthew P. Morrow, David B. Weiner
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c9b11c1863fcf70e1f867a0355e951
https://doi.org/10.1080/21645515.2020.1823778
https://doi.org/10.1080/21645515.2020.1823778
Autor:
Oleg Schmidt-Kittler, Michael Sheets, Yoon-Koo Kang, Chandrasekhar V. Miduturu, Richard D. Kim, Andy Boral, Joseph L. Kim, Nooreen Rubin, Neil Bifulco, Emily Rozsahegyi, Cori Ann Sherwin, Megan A. Hatlen, Natasja Brooijmans, Marion Dorsch, Hongliang Shi, Beni B. Wolf, Klaus P. Hoeflich, Christoph Lengauer, Timothy J. Guzi
Publikováno v:
Cancer Discovery. 9:1686-1695
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfb336958095dcb0a493f3604a752c01
https://doi.org/10.1158/2159-8290.cd-19-0367
https://doi.org/10.1158/2159-8290.cd-19-0367
Autor:
Elena Garralda, Joseph L. Kim, Michael Palmer, Wei Hu, Kevin J. Wilson, Michael Sheets, Douglas Wilson, Marcia S. Brose, Vivek Subbiah, Christoph Lengauer, Justin F. Gainor, Sai-Hong Ignatius Ou, Michelle Maynard, Beni B. Wolf, Paul Fleming, Erica Evans, Jason D. Brubaker, Matthew H. Taylor, Rami Rahal, Mimi I. Hu, Lori J. Wirth, Lucian DiPietro, Stephen D. Miller, Qiongfang Cao, Timothy Guzi
Publikováno v:
Cancer Discovery. 8:836-849
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa86a49748bd34657ea36b58384cc476
https://doi.org/10.1158/2159-8290.cd-18-0338
https://doi.org/10.1158/2159-8290.cd-18-0338
Autor:
Beni B. Wolf, Cori-Ann Sherwin, Natasja Brooijmans, Christoph Lengauer, Hongliang Shi, Megan A. Hatlen, Michael Sheets, Neil Bifulco, Emily Rozsahegyi, Chandra Miduturu, Yoon-Koo Kang, Marion Dorsch, Richard D. Kim, Nooreen Rubin, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Andy Boral, Joseph L. Kim, Timothy J. Guzi
Publikováno v:
Molecular Cancer Therapeutics. 18:A118-A118
When on-target resistance mutations occur in response to potent and selective therapeutics, the target is often considered a validated driver of disease. Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide whose drivers re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::705d66d87fd0d1bda277b4d4b0bd2564
https://doi.org/10.1158/1535-7163.targ-19-a118
https://doi.org/10.1158/1535-7163.targ-19-a118